Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Dare Bioscience Inc DARE

Healthcare Biotechnology
Dare Bioscience, Inc. is a biopharmaceutical company. The Company's programs target unmet needs in women's health, primarily in the areas of contraception, sexual health, pelvic pain, fertility, infectious disease, vaginal health and menopause. Its product includes XACIATO (clindamycin phosphate) vaginal gel 2%. XACIATO is a single-dose prescription medication for the treatment of bacterial... see more

Recent & Breaking News (NDAQ:DARE)

Daré Bioscience Regains Compliance with Nasdaq Minimum Bid Price Rule

GlobeNewswire January 30, 2020

Daré Bioscience Schedules Conference Call for January 22, 2020 to Discuss Ovaprene® Licensing Agreement and General Corporate Update

GlobeNewswire January 15, 2020

Bayer and Daré Bioscience Announce Exclusive Licensing Agreement for U.S. Commercial Rights to Ovaprene ®, an Investigational Hormone-Free, Monthly Contraceptive

Business Wire January 13, 2020

Daré Bioscience Announces FDA Clearance of IND Application for DARE-BV1 for Bacterial Vaginosis to Commence Pivotal Phase 3 Clinical Study

GlobeNewswire December 18, 2019

Daré Bioscience Announces Alignment with the FDA on Phase 2b Study Design and Novel Primary Endpoint PRO Instruments to Support the Continued Clinical Development of Sildenafil Cream, 3.6%, a Potential Therapy for Female Sexual Arousal Disorder

GlobeNewswire December 11, 2019

Daré Bioscience Announces Feature Presentation at the15th US-Japan Symposium on Drug Delivery Systems

GlobeNewswire December 10, 2019

Daré Bioscience Closes Previously Announced Acquisition of Microchips Biotech with a First-in-Class Wireless, User-Controlled Drug Delivery Platform

GlobeNewswire November 21, 2019

Daré Bioscience Reports Third Quarter 2019 Financial Results and Provides Company Update

GlobeNewswire November 14, 2019

Daré Bioscience Announces Positive Findings from a Postcoital Test Clinical Study of Ovaprene® Hormone-Free Contraceptive Candidate

GlobeNewswire November 12, 2019

Daré Bioscience Enters into Agreement to Acquire Microchips Biotech Including Its First-in-Class Wireless, User-Controlled Drug Delivery Platform

GlobeNewswire November 11, 2019

Daré Bioscience to Host Third Quarter 2019 Financial Results and Company Update Conference Call and Webcast

GlobeNewswire November 7, 2019

Daré Bioscience Announces Presentation of Two Posters at American Association of Pharmaceutical Scientists 2019 PharmSci 360

GlobeNewswire October 31, 2019

Daré Bioscience and Strategic Science & Technologies Announce Presentation of Positive Findings from Thermography Clinical Study of Sildenafil Cream, 3.6 % in Healthy Women at the Sexual Medicine Society of North America Conference

GlobeNewswire October 28, 2019

Daré Bioscience to Participate in Two Upcoming Investor Conferences

GlobeNewswire October 14, 2019

Daré Bioscience Announces a Poster Presentation on a Pharmacokinetic Study of DARE-FRT1, in Development for Sustained-Release Progesterone Therapy for Pregnancy Maintenance, at the American Society for Reproductive Medicine 2019 Scientific Congress & Expo

GlobeNewswire October 10, 2019

Daré Bioscience to Present an Overview on its Intravaginal Ring (IVR) Technology in Development for Sustained-Release Hormone Therapy and Pregnancy Maintenance at the 9th Annual Partnership Opportunities in Drug Delivery Conference

GlobeNewswire October 7, 2019

Daré Bioscience Announces the Publication of a Pharmacokinetics Study of DARE-VVA1, a Novel Application of Tamoxifen for the Treatment of Vulvar and Vaginal Atrophy, in the International Journal of Pharmaceutics

GlobeNewswire September 11, 2019

Daré Bioscience Announces Completion of its Content Validity Study to Support the Continued Clinical Development of Sildenafil Cream, 3.6%, a Potential Therapy for Female Sexual Arousal Disorder

GlobeNewswire September 9, 2019

Daré Bioscience to Present at the H.C. Wainwright 21st Annual Global Investment Conference

GlobeNewswire September 4, 2019

Daré Bioscience Reports Second Quarter 2019 Financial Results and Company Update

GlobeNewswire August 14, 2019